Jubilant Biosys Ltd.
27 articles about Jubilant Biosys Ltd.
-
Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics
11/11/2021
Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry and in-vitro ADME Service offerings.
-
Sponsored | Business Transformation during a Pandemic: Q&A about Jubilant Biosys’ bold plans wit...
4/23/2021
This is by far the most exciting time in our history as Jubilant Biosys, and certainly the most exciting message Biosys has ever announced simply because of the sheer scale of transformation that we’ve taken on. It’s massive, very achievable, and ultimately truly transformative for us as colleagu... -
Jubilant Biosys and Yale University announce collaboration to accelerate multiple small molecule discovery programs
2/9/2021
Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.
-
Jubilant Biosys Limited Announces The Merger With Jubilant Chemsys Limited
7/28/2020
Jubilant Biosys Limited (“Biosys”), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India.
-
A conversation with Bob Volkmann, Founder of BioPharma Works– remotely managing multi-functional ...
12/6/2019
Saurabh Kapure, Vice President, Business Development, USA for Jubilant Biosys, recently sat down with Bob Volkmann, PhD, Founder and Chief Scientific Officer, at BioPharmaWorks. -
Jubilant Biosys Commences Major Capacity Expansions for its Drug Discovery Services Business
11/28/2019
Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Lifesciences Limited, today announced commencement of two expansion projects in Greater Noida and Bengaluru.
-
Now & Next Issue 1: Jubilant MavuPharma Q&A with Michael Gallatin
7/1/2019
Saurabh Kapure, Vice President, Business Development, USA for Jubilant Biosys, recently sat down with Michael Gallatin, Ph.D., president and co-founder of Mavupharma (Mavu), the drug discovery and development company, to discuss some of the latest developments in the industry and at Mavu.
-
Jubilant Biosys Selects CDD Vault to Communicate Research Data with Customers for Next Five Years
5/8/2019
-
Jubilant Biosys Expands Collaboration With Sanofi in CNS Therapeutic Area
2/13/2019
Collaboration aimed at discovery of small molecule inhibitors targeting neurological disorders
-
Jubilant Biosys Announces Successful Achievement of an Early Milestone Related to One of Their Collaborative Discovery Programs
11/29/2017
The milestone reflects the successful transition of a collaborative program to the next phase in the discovery and development process.
-
Jubilant BioSys Becomes The First Company In India To Install Agilent's Rapidfire/MS Screening Platform
10/20/2016
-
Jubilant BioSys Ltd. And Orion Corporation Announce Unique Collaborative Discovery Program In Pain Management Area
5/13/2014
-
Jubilant BioSys Ltd. Announces Expansion Of Drug Discovery Alliance With Janssen Pharmaceutica N.V.
2/19/2014
-
Jubilant BioSys Ltd. Announces Successful Filing of Investigational New Drug With US-based Endo Pharmaceuticals
8/7/2013
-
Jubilant BioSys Ltd. and Mnemosyne Pharmaceuticals, Inc. Announce Drug Discovery Collaboration
2/21/2012
-
Jubilant BioSys Ltd. and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program
2/9/2012
-
Norgine and Jubilant BioSys Ltd. Announce Discovery Collaboration in Gastrointestinal Therapeutic Area
10/18/2011
-
Jubilant BioSys Ltd. Announces Drug Discovery Alliance in Neuroscience
6/28/2011
-
Jubilant BioSys Ltd. and AstraZeneca PLC Announce Successful Delivery of Early Milestones in Drug Discovery
6/23/2011
-
Jubilant BioSys Ltd. and AstraZeneca AB Announce Successful Delivery of Early Milestones in Drug Discovery
6/23/2011